Back to results
US 2013/0274245 A1Published application
Composition For Prevention of Vasoactivity in the Treatment of Blood Loss and Anemia
OwnerJan BLUMENSTEINinventor
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
OwnerJan BLUMENSTEINinventor
Estimating the term…
The present invention relates to the prevention of cardiovascular and central nervous system side effects in mammals who receive transfusions of hemoglobin based oxygen carriers (HBOC) or stored blood products containing a concentration of hemoglobin sufficient to induce vasoconstriction, by adding a vasoactivity reducing effective amount of one or more phosphodiesterase inhibitors in combination with a calcium channel blocker and/or an alpha agonist, to the circulation, or alternatively to the HBOC or stored blood, thereby preventing the manifestation of vasoactivity attributable to the presence of free tetrameric hemoglobin (Hb).
A process for reducing or preventing vasoactivity induced by the introduction of a composition containing a hemoglobin based oxygen carrier (HBOC), free hemoglobin (Hb), stored blood products having vasoactivity inducing concentrations of free tetrameric hemoglobin, and combinations thereof comprising:
A process for reducing or preventing vasoactivity induced by the introduction, into a patient in need thereof, of a composition containing a hemoglobin based oxygen carrier (HBOC), free hemoglobin (Hb), stored blood products having vasoactivity inducing concentrations of free tetrameric hemoglobin, and combinations thereof comprising:
A vasoactivity reducing composition useful for reducing or preventing vasoactivity induced by the introduction of a composition containing a hemoglobin based oxygen carrier (HBOC), free hemoglobin (Hb), stored blood products having vasoactivity inducing concentrations of free tetrameric hemoglobin, and combinations thereof, said vasoactivity reducing composition comprising:
Dependencies are inferred from the claim text.